Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Synchroneuron Raises $20M in Series B Funding

Published: Wednesday, July 02, 2014
Last Updated: Tuesday, July 08, 2014
Bookmark and Share
Funding supports continued development of SNC-102, a new formulation of acamprosate calcium currently being studied in a Phase 2 trial to treat moderate-to-severe tardive dyskinesia.

Synchroneuron today announced the closing of a $20 million Series B funding round from sole-investor Morningside Technology Ventures Limited. 

“Morningside’s investment in Synchroneuron demonstrates our belief in the potential of SNC-102 to safely and effectively treat neuropsychiatric disorders such as tardive dyskinesia as well as its potential in additional indications,” said Gerald Chan, Chairman of Morningside Technology Ventures. 

Top-line data from Synchroneuron’s Phase 2, multi-center, randomized, double-blind, placebo-controlled trial of SNC-102 is expected early in 2015. Approximately half of the subjects have entered or already completed the study. In addition, Synchroneuron expects to begin open label studies of SNC-102 in Tourette syndrome and post-traumatic stress syndrome (PTSD) to prove the concept of the drug’s broader efficacy for neuropsychiatric disorders potentially related to glutamate/GABA imbalance. 

“SNC-102 has the potential to be the first FDA-approved drug for tardive dyskinesia, a debilitating and often irreversible movement disorder,” said William Kerns, DVM, Chief Executive Officer of Synchroneuron Inc. “In addition, SNC-102’s distinct mechanism of action, which modulates activity of glutamate without producing the toxicity associated with NMDA antagonists or benzodiazepine-like drugs, may translate into a treatment option for patients with Tourette syndrome and PTSD.” 

Funds from the Series B will support the Company’s active formulation improvement program, additional open label studies of SNC-102 and preclinical studies to better understand acamprosate’s pharmacokinetics and mechanism of action through the end of 2016.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Novel Technique for Kidney Research Developed
To better understand how the treatment leads to kidney damage, and possibly prevent it, a team of researchers at Yale School of Medicine developed a new 3D-imaging technique to peer deep into these vital organs.
Microscopic Fish are 3D-Printed to do More Than Swim
Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities.
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
A Better Way to Personalize Bladder Cancer Treatments
Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer.
Breath of Fresh Air for Asthmatics
Researchers hope to develop a platform that will allow a range of drugs to be delivered by inhalation.
Capturing Cell Growth in 3-D
Spinout’s microfluidics device better models how cancer and other cells interact in the body.
Elastic Patch Releases Drugs in a Stretch
Researchers from have developed a drug delivery technology that consists of an elastic patch that can be applied to the skin and will release drugs whenever the patch is stretched.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Liposomes: A Basis for Drugs of the Future
An international group of scientists have recently presented a review of liposomes, microscopic capsules widely used all over the world in the development of new drugs.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!